Vulvovaginitis News and Research

RSS

Pregnancy and oral health: Unveiling the risks and awareness for mothers-to-be

Study examines the impact of pregnancy on oral health, including increased risks of gum disease and tooth decay. It also investigates women's self-assessment of oral health, health literacy, and awareness of the oral health-pregnancy connection.

15 May 2023

Vulvovaginitis and the microbiome: a review of the diagnosis and treatment of acute and recurrent infection

Researchers explored the relationship between microbiome and vulvovaginitis.

11 Apr 2023

SGLT-2 inhibitors do not increase the risk of UTIs in diabetics, concludes study

A new study has shown that SGLT-2 inhibitors used in the treatment of type 2 diabetes do not increase the risk of UTIs over other anti-diabetic medications.

31 Jul 2019

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.

15 Nov 2012

Antifungal resistance of Candida genital isolates on the increase

Resistance to antifungal therapy of genital-infection causing Candida species may be an increasing problem, suggests research presented at the European Academy of Dermatology and Venereology annual congress in Prague, Czech Republic.

3 Oct 2012

Antifungal resistance of Candida genital isolates on the increase

2 Oct 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012